Market Overview

UPDATE: Jefferies Lowers PT on Zoetis on Challenges Ahead


In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Zoetis (NYSE: ZTS), but lowered the price target from $40.00 to 39.00.

In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income investors over the past two years. Q2'13 earnings look tough in this context and we expect most companies to see some pressure. Novartis, Sanofi, Roche, Abbott, AbbVie and Bayer remain high conviction Buy ideas. We have downgraded Bristol-Myers and Pfizer to Hold in this report as part of our update today.”

Zoetis closed on Thursday at $30.92.

Latest Ratings for ZTS

Aug 2019MaintainsHold
Jul 2019MaintainsBuy
Jul 2019DowngradesBuyNeutral

View More Analyst Ratings for ZTS
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings


Related Articles (ZTS)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Statement from RadioShack Regarding Balance Sheet

UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead